50844-81-0

Basic information

• Product Name: (2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID
• Synonyms: AKOS AUF01750;(2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID;TIMTEC-BB SBB011371;VITAS-BB TBB000213;2-(2-Methyl-4-oxo-quinazolin-3-yl)acetic acid
• CAS NO: 50844-81-0
• Molecular Formula: C₁₁H₁₀N₂O₃
• Molecular Weight: 218.21
• Mol File: 50844-81-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID(50844-81-0)
• EPA Substance Registry System: (2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID(50844-81-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 50844-81-0(Hazardous Substances Data)

Usage

General Description

(2-Methyl-4-oxo-4H-quinazolin-3-yl)-acetic acid, also known as picolinic acid, is a chemical compound with the molecular formula C11H9N4O3. It is a derivative of quinazoline and is used in the synthesis of various pharmaceuticals and organic compounds. The compound is a weak acid and forms salts with various metals, which can be used as chelating agents. Picolinic acid has also been studied for its potential as a treatment for various conditions, including neurodegenerative diseases and cancer. Additionally, it has been investigated for its role in the immune system and inflammation. Overall, (2-Methyl-4-oxo-4H-quinazolin-3-yl)-acetic acid has diverse uses and potential therapeutic applications in the field of medicine and biochemistry.

Upstream product

• 525-76-8 2-methyl-4-oxo-3,1-benzoxazine 
• 112-36-7 3,6,9-trioxaundecane 
• 56-40-6 glycine 
• 50844-82-1 methyl 2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetate 
• 1769-24-0 2-methyl-4-quinazolone 
• 118-92-3 anthranilic acid 
• 89-52-1 o-acetylamino-benzoic acid 

Downstream Products

• 63265-69-0 2-(2-methyl-4-oxoquinazolin-3(4H)-yl)-N-phenylacetamide 
• 106924-08-7 3-(5-p-chlorophenoxymethyl-1,3,4-oxadiazol-2-ylmethyl)-2-methyl-4(3H)-quinazolinone 
• 106924-03-2 3-(5-o-chlorophenyl-1,3,4-oxadiazol-2-ylmethyl)-2-methyl-4(3H)-quinazolinone 
• 106924-05-4 3-(5-p-anisyl-1,3,4-oxadiazol-2-ylmethyl)-2-methyl-4(3H)-quinazolinone 
• 106924-06-5 3-(5-(p-hydroxyphenyl)-1,3,4-oxadiazol-2-ylmethyl)-2-methyl-4(3H)-quinazolinone 
• 106924-07-6 3-(5-benzyl-1,3,4-oxadiazol-2-ylmethyl)-2-methyl-4(3H)-quinazolinone 
• 106924-04-3 3-(5-p-tolyl-1,3,4-oxadiazol-2-ylmethyl)-2-methyl-4(3H)-quinazolinone 
• 106924-02-1 3-(5-phenyl-1,3,4-oxadiazol-2-ylmethyl)-2-methyl-4(3H)-quinazolinone 
• 16353-15-4 2-methyl-4-oxoquinazoline-3-acetic acid hydrazide 
• 40889-43-8 ethyl 2-methyl-4-oxo-3,4-dihydroquinazoline-3-acetate 

Relevant articles and documents

Development of 2-(4-oxoquinazolin-3(4 H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis

InhA, the enoyl acyl carrier protein reductase of Mycobacterium tuberculosis (MTB) is an attractive target for developing novel anti-tubercular agents. Twenty eight 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives were synthesized and evaluated for their in vitro MTB InhA inhibition. Compounds were further evaluated for their in vitro activity against drug sensitive and resistant MTB strains and cytotoxicity against RAW 264.7 cell line. Compounds were docked at the active site of InhA to understand their binding mode and differential scanning fluorimetry was performed to ascertain their protein interaction and stability.

Synthesis of thiadiazolo derivatives of 4-(3h)-quinazolinone as potential antimicrobial agents

-

SYNTHESIS OF PEPTIDES CONTAINING A QUINAZOLIN-4-ONE MOIETY

-